CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic peptide medication that signals your body to produce more growth hormone naturally. Unlike taking growth hormone directly, this medication works by telling your pituitary gland (a small gland at the base of your brain) to release more of your own growth hormone. It's important to know that CJC-1295 is not approved by the FDA, which means it hasn't gone through the full testing process that most medications undergo. It's considered an investigational or experimental treatment that some doctors may prescribe through specialized compounding pharmacies.

How Does It Work and What Is It Used For?

CJC-1295 works by mimicking a natural hormone in your body called growth hormone-releasing hormone (GHRH). When you inject CJC-1295 under your skin, it travels to your pituitary gland and tells it to release more growth hormone. This increase in growth hormone can then help your body build muscle, reduce fat (especially around your belly), improve recovery from exercise, and potentially enhance overall body composition. Some people use it to help with age-related decline in growth hormone, to improve athletic performance, or to help with certain medical conditions affecting body fat distribution. However, because it's not FDA-approved, these uses are considered experimental, and the long-term safety and effectiveness are not fully understood.

How to Take CJC-1295

CJC-1295 comes as a powder that must be mixed with sterile water before use. Your healthcare provider will show you how to mix it properly and how to inject it under your skin, similar to how people with diabetes inject insulin. Common injection sites include your belly (at least 2 inches away from your belly button), thigh, or upper arm. You should rotate where you inject to avoid skin problems. There are two main types: one that you inject once or twice per week (CJC-1295 with DAC), and another shorter-acting version that you might inject 1-3 times daily (Modified GRF 1-29). Your doctor will tell you which type and how often to inject based on your specific situation. Always store the unmixed powder and mixed solution in the refrigerator.

Common Side Effects and When to Call Your Doctor

The most common side effects include redness, pain, or swelling where you inject, water retention that makes your hands or feet swell, headaches, joint aches, tingling or numbness in your hands or feet, and feeling tired or changes in your energy level. These effects are usually mild and may improve as your body adjusts. However, you should call your doctor right away if you experience severe headaches, vision changes, difficulty breathing, severe swelling, chest pain, severe joint pain, or signs of high blood sugar like excessive thirst and frequent urination. Because CJC-1295 increases growth hormone, there are theoretical concerns about it potentially affecting cancer risk, though this hasn't been proven. You should not use this medication if you have cancer, are pregnant or breastfeeding, have uncontrolled diabetes, or have serious heart or kidney problems. Always tell your doctor about all your medical conditions and other medications before starting CJC-1295.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that was developed to overcome the extremely short half-life of native GHRH, which is degraded within minutes of administration. The compound was originally synthesized and characterized by ConjuChem Biotechnologies in the early 2000s as part of research into long-acting GHRH analogs for therapeutic applications. Two primary forms exist: CJC-1295 with Drug Affinity Complex (DAC), which has an extended half-life of approximately 6-8 days, and modified GRF 1-29 (MOD GRF 1-29) without DAC, which has a half-life of approximately 30 minutes but maintains resistance to enzymatic degradation.

CJC-1295 has never received FDA approval for any indication and remains an investigational compound. It is not available through conventional pharmaceutical channels and is primarily obtained through compounding pharmacies or research chemical suppliers. Despite its non-approved status, the compound has been investigated in clinical research settings for several potential therapeutic applications, including HIV-associated lipodystrophy and visceral obesity, age-related growth hormone deficiency, sarcopenia, and metabolic disorders. The compound has also gained attention in anti-aging medicine, sports performance enhancement, and body composition optimization, though these uses lack robust clinical validation and regulatory approval.

The theoretical advantages of CJC-1295 over direct growth hormone administration include preservation of physiological pulsatile secretion patterns, lower cost, potential for fewer side effects related to continuous GH elevation, and maintenance of the body's natural feedback mechanisms. However, the lack of FDA approval, limited long-term safety data, and absence of standardized pharmaceutical-grade manufacturing present significant concerns for clinical use. The compound's use remains controversial within mainstream medicine, with most applications occurring in wellness clinics, anti-aging practices, and athletic performance contexts.

Current clinical interest in CJC-1295 focuses on its potential role in managing conditions characterized by growth hormone insufficiency or metabolic dysfunction. Research has explored its effects on body composition, particularly in reducing visceral adipose tissue while preserving or increasing lean muscle mass. The compound's ability to stimulate endogenous GH production rather than replacing it entirely represents a potentially more physiological approach to GH augmentation, though comprehensive clinical trials demonstrating safety and efficacy for specific indications remain limited.

CJC-1295 functions as a growth hormone-releasing hormone (GHRH) analog that binds to and activates GHRH receptors located on somatotroph cells in the anterior pituitary gland. Upon receptor binding, the compound initiates a G-protein coupled receptor (GPCR) signaling cascade, specifically activating adenylyl cyclase through Gs proteins, which increases intracellular cyclic AMP (cAMP) levels. This elevation in cAMP activates protein kinase A (PKA), leading to phosphorylation of transcription factors that promote growth hormone gene expression and stimulate the release of stored growth hormone from secretory granules.

The distinguishing feature of CJC-1295 is its structural modification that provides resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), the primary enzyme responsible for rapid GHRH breakdown. The original CJC-1295 with Drug Affinity Complex (DAC) includes a lysine linker that allows covalent binding to serum albumin, significantly extending its half-life from minutes to several days. The modified version without DAC (MOD GRF 1-29) maintains the DPP-4 resistance but has a shorter half-life, more closely mimicking physiological GH pulses.

The downstream effects of CJC-1295-induced growth hormone release include stimulation of insulin-like growth factor-1 (IGF-1) production in the liver and peripheral tissues. IGF-1 mediates many of the anabolic effects traditionally attributed to growth hormone, including increased protein synthesis, enhanced lipolysis, improved bone mineral density, and promotion of lean muscle mass. The compound preserves the pulsatile nature of GH secretion rather than providing continuous elevation, which may offer advantages in maintaining receptor sensitivity and reducing potential adverse effects associated with sustained supraphysiological GH levels.

Important Dosing Considerations

CJC-1295 is not FDA-approved, and no official dosing guidelines exist. The following information is based on research protocols, investigational use, and clinical experience reported in the literature. Dosing should only be undertaken under appropriate medical supervision with informed consent regarding the investigational nature of this compound.

Formulation and Preparation

CJC-1295 is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water or sterile saline prior to administration. Standard reconstitution involves adding 2-3 mL of bacteriostatic water to a vial containing 2-5 mg of peptide powder. The vial should be gently swirled (not shaken) until the powder is completely dissolved. Reconstituted solution should be stored refrigerated at 2-8°C and used within 30 days.

Dosing by Formulation Type

CJC-1295 with DAC (Long-Acting)

Modified GRF 1-29 (CJC-1295 without DAC)

Administration Technique

Subcutaneous injection should be administered in areas with adequate subcutaneous tissue, such as the abdomen (at least 2 inches from the umbilicus), thigh, or upper arm. Injection sites should be rotated to prevent lipohypertrophy or lipoatrophy. The area should be cleaned with alcohol prior to injection. A small insulin syringe (typically 0.5-1 mL with 28-31 gauge needle) is appropriate for administration.

Special Population Considerations

Renal Impairment: No specific dosing adjustments have been established. Given renal elimination of peptide metabolites, caution and potential dose reduction may be warranted in moderate to severe renal impairment.

Hepatic Impairment: No specific adjustments established, though hepatic function may affect IGF-1 production and GH responsiveness.

Geriatric Patients: Older adults may have altered GH responsiveness and increased sensitivity to adverse effects. Conservative initial dosing is recommended.

Pediatric Patients: Use in pediatric populations is not recommended due to lack of safety data and potential effects on normal growth and development.

Monitoring During Treatment

Patients receiving CJC-1295 should undergo baseline and periodic monitoring including: IGF-1 levels (to assess response and avoid excessive elevation), fasting glucose and HbA1c (to monitor for glucose intolerance), thyroid function tests, complete blood count, and comprehensive metabolic panel. Clinical monitoring should include assessment of injection site reactions, fluid retention, joint pain, and any signs of excessive GH effects.

Clinical evidence for CJC-1295 remains limited, with most data derived from small-scale studies and case series rather than large randomized controlled trials. The most substantial clinical investigation involved a Phase II study examining CJC-1295 with DAC in patients with HIV-associated lipodystrophy and visceral obesity. This study evaluated the compound's effects on body composition, metabolic parameters, and safety profile in a population characterized by abnormal fat distribution and metabolic dysfunction. Results suggested potential benefits in reducing visceral adipose tissue and improving body composition parameters, though the study was limited by small sample size and relatively short duration.

Pharmacodynamic studies in healthy volunteers have demonstrated that CJC-1295 with DAC produces sustained elevations in growth hormone and IGF-1 levels following single-dose administration. One study showed that a single subcutaneous injection resulted in 2-10 fold increases in mean GH levels and 1.5-3 fold increases in IGF-1 concentrations, with effects persisting for up to 14 days. These findings confirmed the compound's mechanism of action and extended duration of effect, supporting its potential as a long-acting GHRH analog. However, the clinical significance of these biochemical changes and their translation to meaningful therapeutic outcomes remains incompletely characterized.

The absence of large-scale, long-term clinical trials represents a significant gap in the evidence base for CJC-1295. No studies have definitively established efficacy for specific FDA-recognized indications, and comparative effectiveness data against approved therapies (such as recombinant human growth hormone) are lacking. Safety data are primarily limited to short-term observations in small cohorts, with insufficient information regarding long-term adverse effects, cancer risk, cardiovascular outcomes, or metabolic complications. The extracted clinical data indicates investigation in HIV-associated visceral obesity, but specific dosing protocols, efficacy endpoints, and safety outcomes from this research are not fully detailed in available literature.

Anecdotal reports and observational data from wellness clinics and anti-aging practices suggest potential benefits for body composition, recovery from exercise, sleep quality, and subjective well-being. However, these reports lack the rigor of controlled clinical trials and are subject to significant bias, placebo effects, and confounding variables. The compound's use in athletic performance enhancement has been documented, leading to its prohibition by the World Anti-Doping Agency (WADA), though evidence of actual performance benefits remains largely anecdotal. Until comprehensive clinical trials are conducted with appropriate endpoints, control groups, and long-term follow-up, the clinical evidence for CJC-1295 must be considered preliminary and insufficient to support routine therapeutic use.

Absolute Contraindications

CJC-1295 is contraindicated in patients with active malignancy or history of cancer, as growth hormone and IGF-1 can potentially stimulate tumor growth and proliferation. The compound should not be used in patients with known hypersensitivity to CJC-1295 or any component of the formulation. Pregnancy and breastfeeding represent absolute contraindications due to unknown effects on fetal development and potential transfer into breast milk. Patients with active critical illness, including those recovering from major surgery, trauma, or acute respiratory failure, should not receive CJC-1295 due to potential adverse effects on recovery and metabolism. Pediatric use is contraindicated due to lack of safety data and potential interference with normal growth and development.

Relative Contraindications and Warnings

Careful consideration and enhanced monitoring are warranted in patients with diabetes mellitus or impaired glucose tolerance, as CJC-1295 may affect insulin sensitivity and glucose metabolism, potentially worsening glycemic control. Patients with cardiovascular disease should be monitored closely, as fluid retention and potential effects on cardiac function have been reported with growth hormone elevation. Those with carpal tunnel syndrome or history of this condition may experience worsening symptoms due to fluid retention and soft tissue swelling. Patients with sleep apnea may experience exacerbation of symptoms. Hypothyroidism should be adequately treated before initiating CJC-1295, as thyroid hormone status affects GH responsiveness.

Common Adverse Effects

The most frequently reported adverse effects include injection site reactions (redness, swelling, pain, or itching at injection sites), occurring in approximately 20-40% of users. Fluid retention and peripheral edema are common, manifesting as swelling of hands, feet, or ankles. Headaches, typically mild to moderate in severity, have been reported in 10-20% of users. Joint pain or arthralgia may occur, particularly in weight-bearing joints. Numbness or tingling in extremities (paresthesias) can develop, often related to fluid retention and nerve compression. Fatigue or changes in energy levels may occur during initial treatment. Increased hunger or changes in appetite have been reported. Mild nausea, particularly with initial doses, affects some users.

Serious Adverse Effects

Potentially serious adverse effects requiring immediate medical attention include signs of hypersensitivity reactions (difficulty breathing, severe rash, facial swelling), severe or persistent headaches that could indicate increased intracranial pressure, vision changes or eye pain, severe joint pain or reduced range of motion, signs of carpal tunnel syndrome (severe numbness, weakness in hands), symptoms of hyperglycemia (excessive thirst, frequent urination, unexplained weight loss), and chest pain or palpitations. The theoretical risk of promoting tumor growth or cancer progression, while not definitively established in clinical studies, remains a significant concern requiring vigilance.

Monitoring Parameters

Comprehensive monitoring should include baseline and periodic (every 3-6 months) assessment of IGF-1 levels to ensure appropriate response without excessive elevation. Fasting glucose and HbA1c should be monitored to detect glucose intolerance or diabetes development. Thyroid function tests (TSH, free T4) should be checked as GH can affect thyroid hormone metabolism. Lipid panels may reveal changes in cholesterol and triglycerides. Blood pressure monitoring is important due to potential fluid retention effects. Clinical examination should assess for edema, joint swelling, injection site reactions, and signs of carpal tunnel syndrome.

Special Populations

Pregnancy (Category Unknown): CJC-1295 should not be used during pregnancy due to unknown effects on fetal development and lack of safety data. Women of childbearing potential should use effective contraception during treatment.

Lactation: It is unknown whether CJC-1295 or its metabolites are excreted in breast milk. Breastfeeding should be discontinued if treatment is necessary.

Geriatric: Older adults may be more susceptible to adverse effects, particularly fluid retention, joint pain, and glucose intolerance. Conservative dosing and enhanced monitoring are recommended.

Renal Impairment: Patients with kidney disease may have altered clearance of peptide metabolites and increased risk of adverse effects.

Hepatic Impairment: Liver disease may affect IGF-1 production and overall response to treatment, requiring careful monitoring.

Pharmacokinetics

The pharmacokinetic profile of CJC-1295 varies significantly depending on whether the Drug Affinity Complex (DAC) modification is present. CJC-1295 with DAC exhibits an extended elimination half-life of approximately 6-8 days due to covalent binding to serum albumin through the lysine linker, which creates a depot effect and provides sustained release of the active peptide. This modification results in prolonged elevation of growth hormone and IGF-1 levels following a single administration. In contrast, modified GRF 1-29 (CJC-1295 without DAC) has a half-life of approximately 30 minutes, though this represents a significant improvement over native GHRH's half-life of less than 10 minutes.

Following subcutaneous administration, CJC-1295 with DAC reaches peak plasma concentrations within 1-2 hours, with maximum growth hormone elevation occurring 2-6 hours post-injection. The compound demonstrates good bioavailability via subcutaneous route, estimated at 75-90% based on pharmacokinetic modeling. The volume of distribution is relatively limited due to albumin binding, primarily confined to the vascular and interstitial compartments. Metabolism occurs through proteolytic degradation by various peptidases, though the compound's structural modifications provide significant resistance to DPP-4, the primary enzyme responsible for rapid GHRH degradation. Elimination occurs primarily through renal filtration of metabolized peptide fragments, with minimal intact compound excreted in urine.

Pharmacodynamics

The pharmacodynamic effects of CJC-1295 are characterized by dose-dependent increases in growth hormone secretion and subsequent elevation of IGF-1 levels. Studies have demonstrated that CJC-1295 with DAC can maintain elevated IGF-1 levels for up to 14 days following a single injection, with increases ranging from 1.5 to 3-fold above baseline depending on dose. The compound preserves the pulsatile nature of GH secretion, with enhanced amplitude of GH pulses rather than continuous elevation, which may help maintain GH receptor sensitivity and reduce tachyphylaxis.

Drug Interactions and Special Considerations

Potential drug interactions include compounds that affect growth hormone or IGF-1 signaling pathways. Concurrent use with glucocorticoids may attenuate the anabolic effects of CJC-1295 through antagonism of GH action. Thyroid hormone status can influence GH responsiveness, and hypothyroidism may reduce the efficacy of GHRH analogs. Insulin and glucose metabolism may be affected, requiring monitoring in patients using antidiabetic medications. The compound's effects on fluid retention and potential impact on blood pressure should be considered when used with antihypertensive medications. No formal drug interaction studies have been conducted, and caution is warranted when combining CJC-1295 with any medication affecting endocrine function or metabolic homeostasis.